Online inquiry

IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7046MR)

This product GTTS-WQ7046MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets VEGFA gene. The antibody can be applied in Age-related macular degeneration (AMD), Diabetic retinopathy research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7422
UniProt ID P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ7046MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11689MR IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MHAB5553A
GTTS-WQ3182MR IVTScrip™ mRNA-Anti-ANPEP, ARENEGYR(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ARENEGYR
GTTS-WQ6975MR IVTScrip™ mRNA-Anti-pagA, ETI-204(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ETI-204
GTTS-WQ12359MR IVTScrip™ mRNA-Anti-EGFR, N63Ab(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA N63Ab
GTTS-WQ738MR IVTScrip™ mRNA-Anti-APP, AAB-001(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AAB-001
GTTS-WQ14246MR IVTScrip™ mRNA-Anti-ERBB3, RG-7116(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA RG-7116
GTTS-WQ9818MR IVTScrip™ mRNA-Anti-BTLA, JS004(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA JS004
GTTS-WQ9128MR IVTScrip™ mRNA-Anti-MUC1, IMGN242(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IMGN242
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW